Literature DB >> 9669506

Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters.

J C Béïque1, N Lavoie, C de Montigny, G Debonnel.   

Abstract

In vitro radioligand binding studies were carried out in rat brain membranes to assess the affinity of various reuptake inhibitors for the serotonin (5-hydroxytryptamine, 5-HT) and the norepinephrine transporters using the selective ligands [3H]cyanoimipramine and [3H]nisoxetine, respectively. The selective 5-HT reuptake inhibitors paroxetine, indalpine and fluvoxamine displayed a high affinity for the 5-HT transporter, whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the norepinephrine transporter. Duloxetine, a dual 5-HT and norepinephrine reuptake inhibitor, displayed a high affinity for both the 5-HT and the norepinephrine transporters. Interestingly, venlafaxine, a dual 5-HT and norepinephrine reuptake inhibitor, displayed only a moderate affinity for the 5-HT transporter (Ki = 74 nM) and a very low affinity for the norepinephrine transporter (Ki = 1.26 microM). The relatively low affinities of venlafaxine contrast with its potent in vivo 5-HT and norepinephrine reuptake blocking properties. These results raise the possibility that the in vivo effects on the 5-HT and norepinephrine reuptake observed with venlafaxine may not be mediated solely by its binding to the [3H]cyanoimipramine and [3H]nisoxetine binding sites.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9669506     DOI: 10.1016/s0014-2999(98)00241-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  17 in total

1.  WAY-318068: a novel, potent and selective noradrenaline re-uptake inhibitor with activity in rodent models of pain and depression.

Authors:  G T Whiteside; J M Dwyer; J E Harrison; C E Beyer; T Cummons; L Manzino; L Mark; G H Johnston; B W Strassle; A Adedoyin; P Lu; M J Piesla; C M Pulicicchio; J C L Erve; B J Platt; Z A Hughes; K E Rogers; D C Deecher; E J Trybulski; J D Kennedy; P Zhang; L Leventhal
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

2.  Differential inhibitory effects of drugs acting at the noradrenaline and 5-hydroxytryptamine transporters in rat and human neocortical synaptosomes.

Authors:  M Mantovani; D J Dooley; A Weyerbrock; R Jackisch; T J Feuerstein
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

3.  Paroxetine for somatic pain associated with physical illness: a review.

Authors:  Prakash S Masand; Meera Narasimhan; Ashwin A Patkar
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

Review 4.  Venlafaxine extended-release: a review of its use in the management of major depression.

Authors:  K Wellington; C M Perry
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

5.  Chronic serotonin-norepinephrine reuptake transporter inhibition modifies basal respiratory output in adult mouse in vitro and in vivo.

Authors:  Kelly A Warren; Irene C Solomon
Journal:  Respir Physiol Neurobiol       Date:  2012-07-31       Impact factor: 1.931

6.  Lack of association between the norepinephrine transporter gene and major depression in a Han Chinese population.

Authors:  Chuan-Chia Chang; Ru-Band Lu; Chih-Lun Chen; Chi-Ming Chu; Hsin-An Chang; Cheng-Chang Huang; Yi-Lin Huang; San-Yuan Huang
Journal:  J Psychiatry Neurosci       Date:  2007-03       Impact factor: 6.186

7.  Architectonic distribution of the serotonin transporter within the orbitofrontal cortex of the vervet monkey.

Authors:  B M Way; G Laćan; L A Fairbanks; W P Melega
Journal:  Neuroscience       Date:  2007-07-17       Impact factor: 3.590

8.  Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex.

Authors:  Tracy M Felton; Tommy B Kang; Stephan Hjorth; Sidney B Auerbach
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-04       Impact factor: 3.000

9.  Region-specific regulation of 5-HT1B receptors in the rat brain by chronic venlafaxine treatment.

Authors:  R Vidal; A Diaz; A Pazos; E Castro
Journal:  Psychopharmacology (Berl)       Date:  2013-04-23       Impact factor: 4.530

10.  Pharmacological properties of the active metabolites of the antidepressants desipramine and citalopram.

Authors:  Jean D Deupree; Megan D Montgomery; David B Bylund
Journal:  Eur J Pharmacol       Date:  2007-08-23       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.